Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Vertex (VRTX) Gets French Reimbursement For CF Drug Orkambi

By Zacks Investment ResearchStock MarketsNov 20, 2019 10:24PM ET
www.investing.com/analysis/vertex-vrtx-gets-french-reimbursement-for-cf-drug-orkambi-200487060
Vertex (VRTX) Gets French Reimbursement For CF Drug Orkambi
By Zacks Investment Research   |  Nov 20, 2019 10:24PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced an agreement with the French Authorities for national reimbursement of its cystic fibrosis (CF) medicine Orkambi to treat patients aged above 2 years with two copies of the F508del mutation. Management stated that once the agreement gets published in the French Official Journal, Orkambi will be available for all eligible patients.

The French reimbursement for Orkambi removes a key overhang from the stock as France was among the last nations with large CF patient populations not getting a formalized reimbursement for Orkambi.

This year so far, the stock has rallied 29.8% compared with the industry’s increase of 4.3%.

The last couple of months have been impressive for Vertex. As far as reimbursement approvals in the European countries are concerned, Vertex entered into new reimbursement agreements for Orkambi and its another CF medicine Symkevi in England, Spain, Australia and Scotland during September/October 2019, which should drive its outside U.S. revenues in the future quarters.

Meanwhile, last month, Vertex gained FDA approval for its fourth medicine Trikafta to treat CF. The drug is a triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor). With this approval, Vertex can address a significantly larger CF patient population — almost 90% patients — ahead. With the nod to Trikafta, approximately 45,000 patients worldwide are now eligible to be treated with one of Vertex’s four CF medicines.

Earlier this week, Vertex and partner CRISPR Therapeutics AG (NASDAQ:CRSP) announced positive preliminary safety and efficacy data from the ongoing phase I/II studies evaluating their CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders, namely sickle cell disease (SCD) and adult transfusion-dependent b-thalassemia (TDT)

Vertex sports a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.

Other top-ranked stocks in the biotech sector include Anika Therapeutics Inc. (NASDAQ:ANIK) and Alkermes plc (NASDAQ:ALKS) , both flaunting the same Zacks Rank as Vertex.

Anika’s earnings estimates have been revised 16% upward for 2019 and 19.1% for 2020 over the past 60 days. The stock has soared 74.1% so far this year.

Alkermes’ earnings estimates have been revised upward from 36 cents to 52 cents for 2019 while the same for 2020 reversed the loss of 11 cents to earnings of 59 cents over the past 60 days.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>



Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report

CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report

Original post

Zacks Investment Research
Vertex (VRTX) Gets French Reimbursement For CF Drug Orkambi
 

Related Articles

Vertex (VRTX) Gets French Reimbursement For CF Drug Orkambi

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email